Diabetes mellitus type 2 pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 90: Line 90:
== Associated Conditions ==
== Associated Conditions ==


* [[Diabetes mellitus type 2]] is often associated with [[obesity]] and [[hypertension]] and elevated [[cholesterol]] ([[combined hyperlipidemia]]), and with the condition [[Metabolic syndrome]]. It is also associated with [[acromegaly]], [[Cushing's syndrome]], [[Non-alcoholic fatty liver disease|Nonalcoholic steatohepatitis]]([[Non-alcoholic fatty liver disease|NASH]]) and a number of other [[endocrinology|endocrinological]] disorders.<ref name="YounossiGolabi2019">{{cite journal|last1=Younossi|first1=Zobair M.|last2=Golabi|first2=Pegah|last3=de Avila|first3=Leyla|last4=Paik|first4=James Minhui|last5=Srishord|first5=Manirath|last6=Fukui|first6=Natsu|last7=Qiu|first7=Ying|last8=Burns|first8=Leah|last9=Afendy|first9=Arian|last10=Nader|first10=Fatema|title=The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis|journal=Journal of Hepatology|volume=71|issue=4|year=2019|pages=793–801|issn=01688278|doi=10.1016/j.jhep.2019.06.021}}</ref>


*[[Diabetes mellitus type 2]] is often associated with [[obesity]] and [[hypertension]] and elevated [[cholesterol]] ([[combined hyperlipidemia]]), and with the condition [[Metabolic syndrome]]. It is also associated with [[acromegaly]], [[Cushing's syndrome]], [[Non-alcoholic fatty liver disease|Nonalcoholic steatohepatitis]]([[Non-alcoholic fatty liver disease|NASH]]) and a number of other [[endocrinology|endocrinological]] disorders.<ref name="YounossiGolabi2019">{{cite journal|last1=Younossi|first1=Zobair M.|last2=Golabi|first2=Pegah|last3=de Avila|first3=Leyla|last4=Paik|first4=James Minhui|last5=Srishord|first5=Manirath|last6=Fukui|first6=Natsu|last7=Qiu|first7=Ying|last8=Burns|first8=Leah|last9=Afendy|first9=Arian|last10=Nader|first10=Fatema|title=The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis|journal=Journal of Hepatology|volume=71|issue=4|year=2019|pages=793–801|issn=01688278|doi=10.1016/j.jhep.2019.06.021}}</ref>
*Additional factors found to increase risk of [[Diabetes mellitus type 2|type 2 diabetes]] include [[Ageing|aging]]<ref>Jack, L., Jr., Boseman, L. & Vinicor, F. Aging Americans and diabetes. A public health and clinical response. ''Geriatrics'' '''2004''', 59, 14-17.</ref>, high-[[fat]] diets<ref>Lovejoy, J. C. The influence of dietary fat on insulin resistance. ''Curr Diab Rep'' '''2002''', 2,435-440.</ref> and a less active lifestyle<ref>Hu, F. B. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 2003, 38,103-108.</ref>.
*Additional factors found to increase risk of [[Diabetes mellitus type 2|type 2 diabetes]] include [[Ageing|aging]]<ref>Jack, L., Jr., Boseman, L. & Vinicor, F. Aging Americans and diabetes. A public health and clinical response. ''Geriatrics'' '''2004''', 59, 14-17.</ref>, high-[[fat]] diets<ref>Lovejoy, J. C. The influence of dietary fat on insulin resistance. ''Curr Diab Rep'' '''2002''', 2,435-440.</ref> and a less active lifestyle<ref>Hu, F. B. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 2003, 38,103-108.</ref>.
* There is a bidirectional relationship between [[Diabetes mellitus]] and [[sarcopenia]]. Numerous factors like accumulation of [[Advanced glycation endproduct|advanced glycation end-product]], [[inflammation]], [[insulin resistance]], vascular [[Complication (medicine)|complications]] and [[Oxidative stress|oxidative injury]] can interfere with muscle health. This impaired muscle health can eventually lead to [[Diabetes mellitus type 2|type 2 diabetes]].<ref name="pmid31372016">{{cite journal| author=Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D| title=Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. | journal=Diabetes Metab Syndr Obes | year= 2019 | volume= 12 | issue=  | pages= 1057-1072 | pmid=31372016 | doi=10.2147/DMSO.S186600 | pmc=6630094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31372016  }}</ref>
* There is a bidirectional relationship between [[Diabetes mellitus]] and [[sarcopenia]]. Numerous factors like accumulation of [[Advanced glycation endproduct|advanced glycation end-product]], [[inflammation]], [[insulin resistance]], vascular [[Complication (medicine)|complications]] and [[Oxidative stress|oxidative injury]] can interfere with muscle health. This impaired muscle health can eventually lead to [[Diabetes mellitus type 2|type 2 diabetes]].<ref name="pmid31372016">{{cite journal| author=Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D| title=Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. | journal=Diabetes Metab Syndr Obes | year= 2019 | volume= 12 | issue=  | pages= 1057-1072 | pmid=31372016 | doi=10.2147/DMSO.S186600 | pmc=6630094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31372016  }}</ref>
Line 99: Line 98:


== Gross Pathology ==
== Gross Pathology ==
On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
 
* Based on a study, the following [[Pancreas|pancreatic]] changes have been reported in patients with [[Diabetes mellitus type 2|type 2 diabetes]], compared to the [[Scientific control|control group]]: <ref name="pmid25950180">{{cite journal| author=Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R| title=Altered volume, morphology and composition of the pancreas in type 2 diabetes. | journal=PLoS One | year= 2015 | volume= 10 | issue= 5 | pages= e0126825 | pmid=25950180 | doi=10.1371/journal.pone.0126825 | pmc=4423920 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25950180  }}</ref>
** 33% reduction in The [[mean]] [[Pancreas|pancreatic]] volume
** 23% elevation in [[triglyceride]] content
** Serrated borders
** Involution of [[pancreas]]


== Microscopic Pathology ==
== Microscopic Pathology ==
On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
 
* The following [[microscopic]] changes have been found in [[Diabetes mellitus type 2|diabetes type 2]] patients, compared to the normal population: <ref name="pmid259501802">{{cite journal| author=Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R| title=Altered volume, morphology and composition of the pancreas in type 2 diabetes. | journal=PLoS One | year= 2015 | volume= 10 | issue= 5 | pages= e0126825 | pmid=25950180 | doi=10.1371/journal.pone.0126825 | pmc=4423920 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25950180  }}</ref>
**


==References==
==References==

Revision as of 11:24, 1 August 2020

Diabetes mellitus main page

Diabetes mellitus type 2 Microchapters

Home

Patient information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Diabetes Mellitus Type 2 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical therapy

Life Style Modification
Pharmacotherapy
Glycemic Control

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3],Seyedmahdi Pahlavani, M.D. [4]

Overview

The exact pathophysiology of type 2 diabetes mellitus is not fully understood. The underlying pathology is the development of insulin resistance. Contrary to type 1 diabetes, patients with type 2 diabetes sufficiently produce insulin. However, the cellular response to the circulating insulin is diminished in type 2 DM. The mechanism by which the insulin resistance develops is postulated to be influenced by both genetic and environmental factors. Environmental influences on the pathogenesis of type 2 DM include high glycemic diets, central obesity, older age, male gender, low-fiber diet, and highly saturated fat diet.

Pathophysiology

Pathogenesis

Beta-cell function

  • Some carbohydrates are not converted e.g fruit sugar (fructose) is usable as cellular fuel but it is not converted to glucose, and it therefore does not participate in the insulin/glucose metabolic regulatory mechanism.
  • Insulin is used by about two-thirds of the body's cells to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage.
  • If the amount of insulin available is insufficient, if cells respond poorly to the effects of insulin (insulin insensitivity or resistance), or if the insulin itself is defective, then glucose will not be absorbed properly by those body cells that require it nor will it be stored appropriately in the liver and muscles. The net effect is persistent high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis.
Mechanism of insulin release in normal pancreatic beta cells
Mechanism of insulin release in normal pancreatic beta cells

Inflammation and Diabetes

Obesity as the Link Between Diabetes and Inflammation

Systemic Inflammation in Diabetes

Genetics

Associated Conditions

Gross Pathology

Microscopic Pathology

References

  1. Montonen, J.; Knekt, P.; Jarvinen, R.; Reunanen, A. (2004). "Dietary Antioxidant Intake and Risk of Type 2 Diabetes". Diabetes Care. 27 (2): 362–366. doi:10.2337/diacare.27.2.362. ISSN 0149-5992.
  2. van der Schaft, Niels; Schoufour, Josje D.; Nano, Jana; Kiefte-de Jong, Jessica C.; Muka, Taulant; Sijbrands, Eric J. G.; Ikram, M. Arfan; Franco, Oscar H.; Voortman, Trudy (2019). "Dietary antioxidant capacity and risk of type 2 diabetes mellitus, prediabetes and insulin resistance: the Rotterdam Study". European Journal of Epidemiology. 34 (9): 853–861. doi:10.1007/s10654-019-00548-9. ISSN 0393-2990.
  3. Kaneto, H.; Kajimoto, Y.; Miyagawa, J.; Matsuoka, T.; Fujitani, Y.; Umayahara, Y.; Hanafusa, T.; Matsuzawa, Y.; Yamasaki, Y.; Hori, M. (1999). "Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity". Diabetes. 48 (12): 2398–2406. doi:10.2337/diabetes.48.12.2398. ISSN 0012-1797.
  4. 4.0 4.1 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ; et al. (2003). "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance". J Clin Invest. 112 (12): 1821–30. doi:10.1172/JCI19451. PMC 296998. PMID 14679177.
  5. 5.0 5.1 5.2 Calle MC, Fernandez ML (2012). "Inflammation and type 2 diabetes". Diabetes Metab. 38 (3): 183–91. doi:10.1016/j.diabet.2011.11.006. PMID 22252015.
  6. Hotamisligil GS, Shargill NS, Spiegelman BM (1993). "Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance". Science. 259 (5091): 87–91. PMID 7678183.
  7. Rolff J, Siva-Jothy MT (2003). "Invertebrate ecological immunology". Science. 301 (5632): 472–5. doi:10.1126/science.1080623. PMID 12881560.
  8. 8.0 8.1 Berg AH, Scherer PE (2005). "Adipose tissue, inflammation, and cardiovascular disease". Circ Res. 96 (9): 939–49. doi:10.1161/01.RES.0000163635.62927.34. PMID 15890981.
  9. Trayhurn P, Wood IS (2004). "Adipokines: inflammation and the pleiotropic role of white adipose tissue". Br J Nutr. 92 (3): 347–55. PMID 15469638.
  10. Lyssenko, Valeriya; Jonsson, Anna; Almgren, Peter; Pulizzi, Nicoló; Isomaa, Bo; Tuomi, Tiinamaija; Berglund, Göran; Altshuler, David; Nilsson, Peter; Groop, Leif (2008). "Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes". New England Journal of Medicine. 359 (21): 2220–2232. doi:10.1056/NEJMoa0801869. ISSN 0028-4793.
  11. Lyssenko, Valeriya; Jonsson, Anna; Almgren, Peter; Pulizzi, Nicoló; Isomaa, Bo; Tuomi, Tiinamaija; Berglund, Göran; Altshuler, David; Nilsson, Peter; Groop, Leif (2008). "Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes". New England Journal of Medicine. 359 (21): 2220–2232. doi:10.1056/NEJMoa0801869. ISSN 0028-4793.
  12. Das SK, Elbein SC (2006). "The Genetic Basis of Type 2 Diabetes". Cellscience. 2 (4): 100–131. doi:10.1901/jaba.2006.2-100. PMC 1526773. PMID 16892160.
  13. Younossi, Zobair M.; Golabi, Pegah; de Avila, Leyla; Paik, James Minhui; Srishord, Manirath; Fukui, Natsu; Qiu, Ying; Burns, Leah; Afendy, Arian; Nader, Fatema (2019). "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis". Journal of Hepatology. 71 (4): 793–801. doi:10.1016/j.jhep.2019.06.021. ISSN 0168-8278.
  14. Jack, L., Jr., Boseman, L. & Vinicor, F. Aging Americans and diabetes. A public health and clinical response. Geriatrics 2004, 59, 14-17.
  15. Lovejoy, J. C. The influence of dietary fat on insulin resistance. Curr Diab Rep 2002, 2,435-440.
  16. Hu, F. B. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 2003, 38,103-108.
  17. Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D (2019). "Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship". Diabetes Metab Syndr Obes. 12: 1057–1072. doi:10.2147/DMSO.S186600. PMC 6630094 Check |pmc= value (help). PMID 31372016.
  18. Ge, Xiao-Jun; Du, Yu-Xuan; Zheng, Li-Mei; Wang, Mei; Jiang, Jun-Yao (2020). "Mortality trends of liver cancer among patients with type 2 diabetes at the global and national level". Journal of Diabetes and its Complications. 34 (8): 107612. doi:10.1016/j.jdiacomp.2020.107612. ISSN 1056-8727.
  19. Wu, Yingjie; Zhou, An; Tang, Li; Lei, Yuanyuan; Tang, Bo; Zhang, Linjing (2020). "Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes". Journal of Diabetes Research. 2020: 1–11. doi:10.1155/2020/6138438. ISSN 2314-6745.
  20. Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R (2015). "Altered volume, morphology and composition of the pancreas in type 2 diabetes". PLoS One. 10 (5): e0126825. doi:10.1371/journal.pone.0126825. PMC 4423920. PMID 25950180.
  21. Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R (2015). "Altered volume, morphology and composition of the pancreas in type 2 diabetes". PLoS One. 10 (5): e0126825. doi:10.1371/journal.pone.0126825. PMC 4423920. PMID 25950180.


Template:WH Template:WS